Tumor Lysis Syndrome: An Emergency in Pediatric Oncology

Abstract

The tumor lysis syndrome (TLS) is an oncology emergency triggered by a massive and abrupt release of intracellular substances (potassium, phosphate, and purine metabolites) into the bloodstream. It may occur spontaneously or, more frequently, as a consequence of chemotherapy or radiation therapy. When the accumulation of these metabolites overwhelms the normal homeostatic mechanism, the TLS develops and leads to hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcaemia. These metabolic derangements can progress to clinical manifestations including acute renal failure, cardiac arrhythmias, central nervous system toxicity, and even death. The key to prevent and manage TLS is the identification of high-risk patients to give them appropriate treatment measures when necessary.

Keywords

tumor lysis - solid tumor - hematologic malignancies - child

• References

• 1 Jones GL, Will A, Jackson GH, Webb NJA, Rule S ; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 2015; 169 (5) 661-671
• 2 Ahn YH, Kang HJ, Shin HY, Ahn HS, Choi Y, Kang HG. Tumour lysis syndrome in children: experience of last decade. Hematol Oncol 2011; 29 (4) 196-201
• 3 Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011; 61 (5) 287-314
• 4 Latha SM, Krishnaprasadh D, Murugapriya P, Scott JX. Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series. Indian J Nephrol 2015; 25 (2) 91-94
• 5 McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 2012; 5: 75
• 6 Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364 (19) 1844-1854
• 7 Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 2014; 21 (1) 18-26
• 8 Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26 (16) 2767-2778
• 9 Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002; 19 (5) 640-653
• 10 Álvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology (Oxford) 2010; 49 (11) 2010-2015
• 11 Shimada M, Johnson RJ, May Jr WS , et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant 2009; 24 (10) 2960-2964
• 12 Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127 (1) 3-11
• 13 Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16 (12) 3553-3562
• 14 Ejaz AA, Mu W, Kang DH , et al. Could uric acid have a role in acute renal failure?. Clin J Am Soc Nephrol 2007; 2 (1) 16-21
• 15 Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005; 147: 61-68
• 16 Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9 (2) 206-212
• 17 Shaffer SG, Kilbride HW, Hayen LK, Meade VM, Warady BA. Hyperkalemia in very low birth weight infants. J Pediatr 1992; 121 (2) 275-279
• 18 Gennari FJ. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin 2002; 18 (2) 273-288 , vi
• 19 Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012; 7 (10) 1730-1739
• 20 Espay AJ. Neurologic complications of electrolyte disturbances and acid-base balance. Handb Clin Neurol 2014; 119: 365-382
• 21 Cohen R, Ramos R, Garcia C , et al. Electrocardiogram manifestations in hyperkalemia. World J Cardiovasc Dis 2012; 2: 57-63
• 22 Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18 (6) 721-729
• 23 Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289 (25) 1335-1340
• 24 Martin A, Acierno MJ. Continuous renal replacement therapy in the treatment of acute kidney injury and electrolyte disturbances associated with acute tumor lysis syndrome. J Vet Intern Med 2010; 24 (4) 986-989
• 25 Boles JM, Dutel JL, Briere J , et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984; 53 (11) 2425-2429
• 26 Cadman EC, Lunberg WB, Bertino JR. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 1977; 62 (2) 283-290
• 27 Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med 2004; 27 (2) 153-160
• 28 Larson RA, Pui C-H. Tumor lysis syndrome: definition, pathogenesis, clinical manifestations, etiology and risk factors. 2012. Available at: http://www.uptodate.com/contents/tumor-lysis-syndrome-prevention-andtreatment?source=search_result&search=tls&selectedTitle=1%7E12
• 29 Burghi G, Berrutti D, Manzanares W. Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare [in Spanish]. Med Intensiva 2011; 35 (3) 170-178
• 30 Dunlay RW, Camp MA, Allon M, Fanti P, Malluche HH, Llach F. Calcitriol in prolonged hypocalcemia due to the tumor lysis syndrome. Ann Intern Med 1989; 110 (2) 162-164
• 31 Annemans L, Moeremans K, Lamotte M , et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003; 44 (1) 77-83
• 32 Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics 2008; 2 (1) 129-141
• 33 Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 2008; 8 (1) 44-51
• 34 Galardy PJ, Hochberg J, Perkins SL, Harrison L, Goldman S, Cairo MS. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report. Br J Haematol 2013; 163 (3) 365-372
• 35 Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011; 154 (1) 3-13
• 36 Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008; 93 (1) 9-13
• 37 Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res 1981; 41 (6) 2273-2279
• 38 Pui CH, Mahmoud HH, Wiley JM , et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19 (3) 697-704
• 39 de Bont JM, Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids 2004; 23 (8–9) 1431-1440
• 40 Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3 (8) 438-447
• 41 Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003; 37 (7–8) 1047-1054
• 42 Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005; 331 (7517) 623-624
• 43 Sanofi-Synthelabo. Elitek (rasburicase) product monograph. Available at: http://products.sanofi-aventis.us/elitek/elitek.html ; Accessed July 23, 2012
• 44 Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 1972; 17 (9) 890-895
• 45 Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002; 3 (4) 433-442
• 46 Goldman SC, Holcenberg JS, Finklestein JZ , et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97 (10) 2998-3003
• 47 Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31 (1) 27-28
• 48 Coiffier B, Mounier N, Bologna S , et al; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21 (23) 4402-4406
• 49 Annemans L, Moeremans K, Lamotte M , et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003; 11 (4) 249-257
• 50 Jeha S, Kantarjian H, Irwin D , et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005; 19 (1) 34-38
• 51 Vadhan-Raj S, Fayad LE, Fanale MA , et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 2012; 23 (6) 1640-1645
• 52 Cairo MS, Coiffier B, Reiter A, Younes A. TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS): in adults and children with malignant disease: an expert TLS panel consensus. Br J Haematol 2010; 149 (4) 578-586
• 53 Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27 (3) 337-343
• 54 Goldman SC, Holcenberg JS, Finklestein JZ , et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97 (10) 2998-3003
• 55 Cheuk DKL, Chiang AKS, Chan GCF, Ha SY. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010; 8 (6) CD006945
• 56 Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003; 82 (3) 160-165